Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of recombinant factor VIII-Fc fusion protein prophylaxis in adolescent and adult hemophilia A
ChiCTR2100045285Phase 3Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of recombinant human coagulation factor viii-fc fusion protein in hemophilia A, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Annualized bleeding rate, Number of target joints and 1 more. Started Apr 2021; status: recruiting.
02
Drugs
recombinant human coagulation factor viii-fc fusion protein
03
Conditions
hemophilia A
Beyond the preview
Go deeper on ChiCTR2100045285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045285.